Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infectionAt a glance commentary
Background: Thrombocytopenia is a common extrahepatic manifestation in chronic liver disease. However, there have been rare studies of impacts of risk for hepatitis C virus-associated thrombocytopenia (HCV-TP) and hepatitis B virus-associated thrombocytopenia (HBV-TP). The aim of this study is to ev...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Biomedical Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S231941702100113X |
| _version_ | 1811232663994892288 |
|---|---|
| author | Cih-En Huang Jung-Jung Chang Yu-Ying Wu Shih-Hao Huang Wei-Ming Chen Chia-Chen Hsu Chang-Hsien Lu Chao-Hung Hung Chung-Sheng Shi Kuan-Der Lee Chih-Cheng Chen Min-Chi Chen |
| author_facet | Cih-En Huang Jung-Jung Chang Yu-Ying Wu Shih-Hao Huang Wei-Ming Chen Chia-Chen Hsu Chang-Hsien Lu Chao-Hung Hung Chung-Sheng Shi Kuan-Der Lee Chih-Cheng Chen Min-Chi Chen |
| author_sort | Cih-En Huang |
| collection | DOAJ |
| description | Background: Thrombocytopenia is a common extrahepatic manifestation in chronic liver disease. However, there have been rare studies of impacts of risk for hepatitis C virus-associated thrombocytopenia (HCV-TP) and hepatitis B virus-associated thrombocytopenia (HBV-TP). The aim of this study is to evaluate different impacts of risk factors for HCV-TP and HBV-TP. Methods: We retrospectively collected 1803 HCV patients and 1652 HBV patients to examine the risk factors for time to moderate and severe thrombocytopenia (platelet counts <100 × 109/L and <50 × 109/L, respectively) by Cox proportional hazards models. Moreover, we prospectively enrolled 63 HCV-TP patients, 11 HBV-TP patients, and 27 HCV controls to detect specific antiplatelet antibodies by enzyme-linked immunosorbent assay and analyze their effects. Results: Prevalence of platelet <100 × 109/L was 11.86% and 6.35% in HCV and HBV patients without cancer history, respectively. HCV-to-HBV incidence rate ratio for thrombocytopenia was 6.95. Initial thrombocytopenia was the most significant risk factor for HCV-TP and HBV-TP regardless of thrombocytopenia severity. Splenomegaly and cirrhosis were significant risk factors for moderate, but not severe HCV-TP. Hyperbilirubinemia was an important moderate and severe HBV-TP risk factor. Antiplatelet antibodies were correlated with HCV-TP severity, of which anti-glycoprotein IIb/IIIa antibody being associated with smaller spleen size. The antiplatelet autoantibody might contribute to thrombocytopenia either independently or with splenomegaly as the important risk in HCV-TP patients without advanced cirrhosis. Conclusion: HCV was associated with higher thrombocytopenia incidence than HBV. Thrombocytopenia risk factors varied with virus type and severity. Different management for HCV-TP and HBV-TP was suggested. |
| first_indexed | 2024-04-12T11:07:57Z |
| format | Article |
| id | doaj.art-8524f9b6dc7849efa8d04f885e89c0b3 |
| institution | Directory Open Access Journal |
| issn | 2319-4170 |
| language | English |
| last_indexed | 2024-04-12T11:07:57Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedical Journal |
| spelling | doaj.art-8524f9b6dc7849efa8d04f885e89c0b32022-12-22T03:35:42ZengElsevierBiomedical Journal2319-41702022-10-01455788797Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infectionAt a glance commentaryCih-En Huang0Jung-Jung Chang1Yu-Ying Wu2Shih-Hao Huang3Wei-Ming Chen4Chia-Chen Hsu5Chang-Hsien Lu6Chao-Hung Hung7Chung-Sheng Shi8Kuan-Der Lee9Chih-Cheng Chen10Min-Chi Chen11Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan; Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, TaiwanDivision of Cardiology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, TaiwanDivision of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, TaiwanDivision of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan; Department of Public Health and Biostatistics Consulting Center, Chang Gung University, Taoyuan, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyuan, TaiwanDivision of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, TaiwanDivision of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyuan, TaiwanDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan; Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, TaiwanDivision of Hematology and Oncology, Department of Internal Medicine, and Cancer Research Center, Taipei Medical University Hospital, Taipei, Taiwan; International Ph.D. Program for Cell Therapy and Regeneration Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, TaiwanDivision of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; Corresponding author. Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, 6, Sec. West, Chia-Pu Rd., Pu-Tz City, Chiayi 61363, Taiwan.Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan; Department of Public Health and Biostatistics Consulting Center, Chang Gung University, Taoyuan, Taiwan; Corresponding author. Department of Public Health and Biostatistics Consulting Center, Chang Gung University, 259, Wenhua 1st Rd., Gueishan, Taoyuan 333, Taiwan.Background: Thrombocytopenia is a common extrahepatic manifestation in chronic liver disease. However, there have been rare studies of impacts of risk for hepatitis C virus-associated thrombocytopenia (HCV-TP) and hepatitis B virus-associated thrombocytopenia (HBV-TP). The aim of this study is to evaluate different impacts of risk factors for HCV-TP and HBV-TP. Methods: We retrospectively collected 1803 HCV patients and 1652 HBV patients to examine the risk factors for time to moderate and severe thrombocytopenia (platelet counts <100 × 109/L and <50 × 109/L, respectively) by Cox proportional hazards models. Moreover, we prospectively enrolled 63 HCV-TP patients, 11 HBV-TP patients, and 27 HCV controls to detect specific antiplatelet antibodies by enzyme-linked immunosorbent assay and analyze their effects. Results: Prevalence of platelet <100 × 109/L was 11.86% and 6.35% in HCV and HBV patients without cancer history, respectively. HCV-to-HBV incidence rate ratio for thrombocytopenia was 6.95. Initial thrombocytopenia was the most significant risk factor for HCV-TP and HBV-TP regardless of thrombocytopenia severity. Splenomegaly and cirrhosis were significant risk factors for moderate, but not severe HCV-TP. Hyperbilirubinemia was an important moderate and severe HBV-TP risk factor. Antiplatelet antibodies were correlated with HCV-TP severity, of which anti-glycoprotein IIb/IIIa antibody being associated with smaller spleen size. The antiplatelet autoantibody might contribute to thrombocytopenia either independently or with splenomegaly as the important risk in HCV-TP patients without advanced cirrhosis. Conclusion: HCV was associated with higher thrombocytopenia incidence than HBV. Thrombocytopenia risk factors varied with virus type and severity. Different management for HCV-TP and HBV-TP was suggested.http://www.sciencedirect.com/science/article/pii/S231941702100113XAntiplatelet antibodyCirrhosisHepatitis B virusHepatitis C virusSpleenThrombocytopenia |
| spellingShingle | Cih-En Huang Jung-Jung Chang Yu-Ying Wu Shih-Hao Huang Wei-Ming Chen Chia-Chen Hsu Chang-Hsien Lu Chao-Hung Hung Chung-Sheng Shi Kuan-Der Lee Chih-Cheng Chen Min-Chi Chen Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infectionAt a glance commentary Biomedical Journal Antiplatelet antibody Cirrhosis Hepatitis B virus Hepatitis C virus Spleen Thrombocytopenia |
| title | Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infectionAt a glance commentary |
| title_full | Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infectionAt a glance commentary |
| title_fullStr | Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infectionAt a glance commentary |
| title_full_unstemmed | Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infectionAt a glance commentary |
| title_short | Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infectionAt a glance commentary |
| title_sort | different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis b virus and hepatitis c virus infectionat a glance commentary |
| topic | Antiplatelet antibody Cirrhosis Hepatitis B virus Hepatitis C virus Spleen Thrombocytopenia |
| url | http://www.sciencedirect.com/science/article/pii/S231941702100113X |
| work_keys_str_mv | AT cihenhuang differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT jungjungchang differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT yuyingwu differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT shihhaohuang differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT weimingchen differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT chiachenhsu differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT changhsienlu differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT chaohunghung differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT chungshengshi differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT kuanderlee differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT chihchengchen differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary AT minchichen differentimpactsofcommonriskfactorsassociatedwiththrombocytopeniainpatientswithhepatitisbvirusandhepatitiscvirusinfectionataglancecommentary |